Posts filtered by tags: GlaxoSmithKline[x]


 

How the finance industry can save the world

For millennia, the finance industry has been a primary culprit in global warming. Now it's time for finance to right its wrongs and provide the solution.It's easy to read about the current and future state of our climate and have a fit of despair. For years, the scientific consensus was that we'd be fine if temperatures increased from pre-industrial levels by less than 2°C. But the UN's recent global warming report revises the threshold, showing that a 1.5°C increase will have catastrophic effec...
Tags: Money, Climate Change, Finance, Environment, US, Unilever, Economics, Sustainability, Innovation, Un, GlaxoSmithKline, Oxford University, Jones, Trump, Myles Allen, Williamson


Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More

Diabetes drugs are Eli Lilly’s bread and butter, but the pharmaceutical giant hasn’t lost its appetite for cancer drugs. It grabbed hold of a few more this week by betting $8 billion on Loxo Oncology.Loxo (NASDAQ: LOXO) has made a name for itself by becoming one of just two companies ever to earn an FDA approval for a drug that targets a tumor’s DNA fingerprint, no matter where in the body that cancer is found. The drug, larotrectinib, targets rare tumor abnormalities known as NTRK fusions. The...
Tags: Deals, Startups, Ipo, Cancer, Trends, Medicare, SEC, Fda, National, GlaxoSmithKline, Allergan, Shire, Biotech, Medical Device, Postpartum Depression, Bernie Sanders


Bio-JPM Roundup: Lilly Buys Loxo, Sage’s Stock Soars, ALS Cash & More

The flow of biotech news is particularly heavy today, and for good reason. The annual J.P. Morgan Healthcare Conference, one of the biggest gatherings for the biopharmaceutical industry, kicked off today in San Francisco, and many companies, whether they’re speaking at the event or not, use this time to get their news out.Xconomy is on the ground covering the conference this week. In the meantime, here’s a short roundup of biotech news announced today.DEALS AND DATA—Eli Lilly (NYSE: LLY) is pay...
Tags: Deals, Startups, San Francisco, Trends, Investing, Vc, Venture Capital, Fda, National, GlaxoSmithKline, Biotech, Postpartum Depression, Life Sciences, Clinical Trials, Celgene, Gilead Sciences


Eli Lilly Makes an $8B Cancer Genetics Bet with Loxo Acquisition

[Updated 1/7/19, 11 a.m. ET. See below.] Eli Lilly is set to acquire Loxo Oncology for approximately $8 billion—a deal that brings to the Indianapolis pharmaceutical giant a class of drugs that treat cancers with particular genetic signatures.Under the agreement announced Monday, Lilly (NYSE: LLY) will pay $235 cash per share of Loxo (NASDAQ: LOXO), which is a 68 percent premium to the Friday closing price of the Stamford, CT, cancer drug developer. Following the news of the deal, shares of Lox...
Tags: Deals, Drugs, Cancer, Trends, Indiana, Indianapolis, Mergers and Acquisitions, Fda, GlaxoSmithKline, Biotech, Life Sciences, Bayer, Clinical Trials, Celgene, American Society of Clinical Oncology, Stamford


Genetic testing is the future of healthcare, but many experts say companies like 23andMe are doing more harm than good

Genetic testing will be a cornerstone of healthcare in 2019, experts say. There are two ways to do the testing: getting a costly but complete genetic workup through a doctor or opting for a cheaper at-home test like those sold by 23andMe. Clinicians and advocates criticize the at-home approach, which they say prioritizes and long-term health. But entrepreneurs counter that the at-home approach lets more people access information. Which method will win out, and at what cost? As millions of A...
Tags: Google, Trends, Food And Drug Administration, Helix, Fda, GlaxoSmithKline, Barry, Ross, 23andMe, Luna, Rogers, Anne Wojcicki, Ancestry, Hazel, Vanderbilt University, Levin


Genetic testing could be the future of healthcare, but some doctors think companies like 23andMe might be doing more harm than good

Genetic testing will be a cornerstone of healthcare in 2019, experts say. There are two ways to do the testing: getting a costly but complete genetic workup through a doctor or opting for a cheaper at-home test like those sold by 23andMe. Clinicians and advocates criticize the at-home approach, which they say prioritizes and long-term health. But entrepreneurs counter that the at-home approach lets more people access information. Which method will win out, and at what cost? As millions of A...
Tags: Google, Trends, Food And Drug Administration, Helix, Fda, GlaxoSmithKline, Barry, Ross, 23andMe, Luna, Rogers, Anne Wojcicki, Ancestry, Hazel, Vanderbilt University, Levin


Genetic Info is Less Valuable Than Social and Search Data

GlaxoSmithKline has invested $300 million into 23andMe. GSK and 23andMe will partner to develop new medicines. They will split costs and profits equally. 23andMe raised $250 million at a $1.75... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Tags: Innovation, GlaxoSmithKline, GSK, Search Data


How to Save $650 Million Without Really Trying

Pfizer and GlaxoSmithKline join forces with their consumer healthcare businesses, creating plenty of synergies.
Tags: Finance, Article, GlaxoSmithKline, Pfizer, FBN, Motley Fool, Fbn/markets, Fox-business/markets, 6c7b5bc0-762d-505d-b604-56a7a009043d


5 things to know about DNA tests before you send your spit

This Christmas, plenty of people will find DNA tests under the tree.  They're easy to use — just send 23andMe, Ancestry, or one of their competitors your spit, and in exchange you're promised a detailed breakdown of your heritage. For a little extra cash, you can learn about your genetic health risks, too.  23andMe and Ancestry are privately held companies that don't disclose sales numbers. But ads for them are all over the internet these days. Last year, Ancestry claimed it sold ...
Tags: Asia, England, Science, Africa, Bloomberg, Philippines, Italy, Denmark, Npr, GlaxoSmithKline, Ancestry, U S Food and Drug Administration, Golden State Killer


GlaxoSmithKline and General Mills climb while FedEx drops

NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday:FedEx Corp., down $22.50 to $162.51The shipping company said international shipping dropped in the last quarter.GlaxoSmithKline PLC, up 31 cents to... [Author: [email protected]]
Tags: Business, New York, Ap, GlaxoSmithKline, General Mills, FedEx Corp, GlaxoSmithKline Plc


Markets Right Now: Stocks move higher as oil price rebounds

NEW YORK (AP) — The latest on developments in financial markets (all times local):11:45 a.m.Stocks are higher on Wall Street as energy companies benefit from a partial recovery in oil prices following a huge loss the day before.GlaxoSmithKline... [Author: [email protected]]
Tags: Business, New York, GlaxoSmithKline


GlaxoSmithKline and Pfizer to Merge Consumer Health Units

The companies say their new venture will be the world’s largest maker of over-the-counter products like pain relievers, toothpastes, cold treatments, vitamins and dietary supplements.
Tags: News, United States, Mergers, GlaxoSmithKline, Pfizer, Great Britain, Pfizer Inc, GlaxoSmithKline Plc, Acquisitions and Divestitures, Vitamins, Dietary Supplements and Herbal Remedies, Drugs (Pharmaceuticals


Pfizer, GSK to Merge Consumer Health Units, Focus on Prescription Drugs

Two of the world’s top drugmakers want to focus on making prescription drugs. Pfizer and GlaxoSmithKline have agreed to merge their consumer health businesses and spin them off into a joint venture, a move that will both create a new consumer healthcare giant and increase the pressure on each company to churn out innovative medicines.GSK (NYSE: GSK) will hold 68 percent of the new company, with Pfizer (NYSE: PFE) getting the remaining 32 percent. The combined company will have some $12.7 billio...
Tags: Deals, Drugs, Trends, National, GlaxoSmithKline, Novartis, Pfizer, Vaccines, Pharma, Life Sciences, GSK, National blog main, New York blog main, Seattle blog main, Boston blog main, National top stories


GSK, Pfizer to merge health care divisions

LONDON (AP) — Drugmakers GlaxoSmithKline and Pfizer are merging their health care divisions, creating a market leader in "over the counter" health care products like pain relievers and vitamins with combined sales of 9.8 billion pounds... [Author: [email protected]]
Tags: Business, London, Ap, GlaxoSmithKline, Pfizer, GSK Pfizer


GSK, Pfizer to merge their healthcare divisions

LONDON (AP) — Drugmakers GlaxoSmithKline and Pfizer are merging their healthcare divisions, creating a business with combined sales of 9.8 billion pounds ($12.7 billion).British-based Glaxo will own 68 percent of the joint venture,... [Author: [email protected]]
Tags: Business, London, Ap, GlaxoSmithKline, Pfizer, Glaxo, GSK Pfizer


Advil meet Excedrin: Pfizer and GSK are merging their consumer healthcare businesses

GlaxoSmithKline and Pfizer are combining their consumer healthcare businesses in a multibillion-dollar merger.
Tags: Cnn, GlaxoSmithKline, Pfizer, GSK


Drugmaker GSK to split after striking Pfizer consumer health deal

GlaxoSmithKline plans to split into two businesses -- one for prescription drugs and vaccines, the other for over-the-counter products -- after forming a new joint venture with Pfizer's consumer health division. The revamp is the boldest move yet by GSK Chief Executive Emma Walmsley, who took over last year. It will lead to the creation of a consumer health giant with a market share of 7.3 percent, well ahead of its nearest rivals Johnson & Johnson, Bayer and Sanofi, all on around 4 percent.
Tags: Science, GlaxoSmithKline, Pfizer, Sanofi, GSK, Emma Walmsley, Johnson Johnson Bayer


GlaxoSmithKline and Pfizer merge healthcare arms

Drug giants GSK and Pfizer are combining their consumer healthcare businesses.
Tags: Business, GlaxoSmithKline, Pfizer, GSK


Drugmaker GSK to split after folding in Pfizer consumer unit

GlaxoSmithKline plans to split into two businesses -- one for prescription drugs and vaccines, the other for over-the-counter products -- after forming a new joint venture with Pfizer's consumer health division.
Tags: Money, businessNews, GlaxoSmithKline, Pfizer, GSK


Healthcare deals hit an all-time record in 2018. See the 7 biggest tie-ups that could change how we buy drugs and treat diseases.

Healthcare dealmaking hit a record this year, and the transactions could reshape how we pay for our prescriptions and treat diseases. Big pharma companies, health insurers, and care providers have agreed to about $421 billion in transactions this year, according to data from Refinitiv. That's a record high, and amounts to 11 percent of all M&A this year. The tally from Refinitiv counts deals when they're announced, though not all transactions are ultimately completed. The dollar figures includ...
Tags: Japan, US, Trends, Cigna, GlaxoSmithKline, Novartis, Shire, GSK, Takeda, Refinitiv


Could These Be the Next 2 Biotech Buyouts?

If GlaxoSmithKline's recent splurge signals a new round of acquisitions, these stocks could be next.
Tags: Finance, Article, GlaxoSmithKline, FBN, Motley Fool, Fbn/markets, Fox-business/markets, D8388d37-3c33-50fa-ae80-2a3373be8ae3


Bio Roundup: ASH Wrap, CRISPR Baby Fallout, Moderna’s Record IPO

The biggest yearly meeting for blood disease research has come and gone, and yet the stories to come out of the American Society of Hematology’s gathering in San Diego represent just a fraction of what happened in biopharma this week.Even if ASH wasn’t on your radar, the CRISPR baby saga—the apparent birth of gene edited twin girls in China that shocked the life sciences world a few weeks ago—rolled on. One massive buyout was signed, and another even bigger one inched closer to being finalized....
Tags: Deals, Startups, China, Ipo, Trends, IPOs, People, Vc, Adhd, San Diego, Astrazeneca, Fda, National, GlaxoSmithKline, Novartis, Ash


$300 million deal selling DNA info to Drug Company

23andme and GlaxoSmithKline working together sharing DNA data. How soon will DNA collecting companies come to same sort of deal with insurance companies and medicare/medicaid? People have been warned not to participate in these data collecting schemes! https://www.businessinsider.com/dna-..._jEkXkX4U4z3tQ (I notice the story is from July, but I hadn't seen it before)
Tags: GlaxoSmithKline, Weapon, General Discussion, Drug Company


Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline

Brii Biosciences launched earlier this year with $260 million and a mission to find new medicines in infectious disease and other therapeutic areas and bring them to China. Today, the startup is announcing new partnerships that jump-start its pipeline, with an eye on potentially curing hepatitis B.Brii, co-founded by GlaxoSmithKline (NYSE: GSK) infectious disease veteran Zhi Hong, has signed a collaboration with VBI Vaccines (NASDAQ: VBIV) of Cambridge, MA to develop VBI-2601, an injectable dru...
Tags: Deals, Startups, China, Trends, Beijing, GlaxoSmithKline, Biotech, Life Sciences, GSK, Tsinghua University, Cambridge MA, Alnylam Pharmaceuticals, VBI, National blog main, Boston blog main, National top stories


OncoMed’s Saga Ends in Reverse Merger with UK-Based Mereo BioPharma

OncoMed Pharmaceuticals attracted hundreds of millions of dollars from investors and pharmaceutical partners with compounds it developed to target cells that drive cancer growth. But after a series of clinical trial stumbles and the dissolution of its drug development alliances over the last two years, OncoMed is now serving as a vehicle for a UK-based company to gain a public listing in the U.S.Redwood City, CA-based OncoMed (NASDAQ: OMED) announced Wednesday an agreement to merge with rare di...
Tags: Deals, UK, London, Ipo, Cancer, San Francisco, Trends, Investing, Ovarian Cancer, Fda, GlaxoSmithKline, Biotech, Pancreatic Cancer, Life Sciences, Bayer, Clinical Trials


GSK slides after buying cancer firm Tesaro for hefty $5.1 billion: Reuters

GlaxoSmithKline has agreed to buy U.S. cancer specialist Tesaro for $5.1 billion, a costly investment to rebuild the pharmaceuticals business by new Chief Executive Emma Walmsley that unnerved investors. GSK has lagged rivals in recent years in producing multibillion-dollar blockbusters and it largely sat out a spate of dealmaking by rival drugmakers under previous CEO Andrew Witty. That is a situation Walmsley wants to change. Britain’s biggest drugmaker is paying $75 a share for Tesaro, an 110...
Tags: Boston, India, Trends, Unilever, Britain, Healthcare, Switzerland, M&a, Astrazeneca, GlaxoSmithKline, Novartis, Citi, Reuters, Genentech, Roche, GSK


Tribune Media, Amazon rise; GlaxoSmithKline, Discovery fall

NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday:Tribune Media Co., up $4.72 to $44.98The TV station owner agreed to be acquired by Nexstar, four months after a bid from Sinclair Broadcast Group collapsed.GlaxoSmithKline... [Author: [email protected]]
Tags: Business, New York, Ap, GlaxoSmithKline, Nexstar, Sinclair Broadcast Group, Tribune Media Co, Tribune Media Amazon, GlaxoSmithKline Discovery


Trump’s trade war truce with China fragile and hurdle-strewn | Nils Pratley

Despite stock markets surging, timeframe for reaching deal to end hostilities appears too tightAs ever with financial markets, what matters is the difference from expectations. Investors did not think the G20 summit would produce an easing of trade tensions between the US and China, therefore stock markets surged after Donald Trump declared that relations had taken “a BIG leap forward”.Yet it is only sensible to believe Trump’s hyperbole when there is something on the table to inspect. All that ...
Tags: Business, China, US, International Trade, Economics, UK News, World news, Retail industry, US news, Asia Pacific, US politics, Global Economy, Mike Ashley, Pharmaceuticals industry, Mergers and Acquisitions, GlaxoSmithKline


ResMed Boosts Connected Health Play With $225M Propeller Health Deal

ResMed has inked a $225 million deal to acquire Propeller Health, in the latest endorsement of Internet-connected devices for healthcare.The acquisition, which is expected to close by the end of March 2019, continues San Diego-based ResMed’s (NYSE: RMD) “connected healthcare” push that began about five years ago, as Xconomy chronicled last year. The medical device company, with a $16 billion market capitalization, is best known for making continuous positive airway pressure (CPAP) machines that...
Tags: Deals, Startups, Mobile, Apps, Internet Of Things, Connected Devices, Trends, Tech, It, Walgreens, Vc, Software, Asthma, Healthcare, San Diego, M&a


GSK slides after buying cancer firm Tesaro for hefty $5.1 billion

GlaxoSmithKline has agreed to buy U.S. cancer specialist Tesaro for $5.1 billion, a costly investment to rebuild the pharmaceuticals business by new Chief Executive Emma Walmsley that unnerved investors.
Tags: Money, businessNews, GlaxoSmithKline, GSK, Tesaro, Emma Walmsley